Ghent University Academic Bibliography

Advanced

Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour

Fiebrich Helle-Brit, Johan R de Jong, Ido P Kema, Klaas Pieter Koopmans, Wim Sluiter, Rudi Dierckx UGent, Annemiek M Walenkamp, Thera P Links, Adrienne H Brouwers and Elisabeth GE de Vries (2011) EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 38(10). p.1854-1861
abstract
Positron emission tomography (PET) using 6-[(18)F]fluoro-L-dihydroxyphenylalanine ((18)F-dopa) has an excellent sensitivity to detect carcinoid tumour lesions. (18)F-dopa tumour uptake and the levels of biochemical tumour markers are mediated by tumour endocrine metabolic activity. We evaluated whether total (18)F-dopa tumour uptake on PET, defined as whole-body metabolic tumour burden (WBMTB), reflects tumour load per patient, as measured with tumour markers. Seventy-seven consecutive carcinoid patients who underwent an (18)F-dopa PET scan in two previously published studies were analysed. For all tumour lesions mean standardised uptake values (SUVs) at 40% of the maximal SUV and tumour volume on (18)F-dopa PET were determined and multiplied to calculate a metabolic burden per lesion. WBMTB was the sum of the metabolic burden of all individual lesions per patient. The 24-h urinary serotonin, urine and plasma 5-hydroxindoleacetic acid (5-HIAA), catecholamines (nor)epinephrine, dopamine and their metabolites, measured in urine and plasma, and serum chromogranin A served as tumour markers. All but 1 were evaluable for WBMTB; 74 patients had metastatic disease. (18)F-dopa PET detected 979 lesions. SUV(max) on (18)F-dopa PET varied up to 29-fold between individual lesions within the same patients. WBMTB correlated with urinary serotonin (r = 0.51) and urinary and plasma 5-HIAA (r = 0.78 and 0.66). WBMTB also correlated with urinary norepinephrine, epinephrine, dopamine and plasma dopamine, but not with serum chromogranin A. Tumour load per patient measured with (18)F-dopa PET correlates with tumour markers of the serotonin and catecholamine pathway in urine and plasma in carcinoid patients, reflecting metabolic tumour activity.
Please use this url to cite or link to this publication:
author
organization
alternative title
Total (18)F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour
year
type
journalArticle (original)
publication status
published
subject
keyword
Carcinoid tumour, (18)F-dopa PET, Whole-body metabolic tumour burden, 5-HIAA, POSITRON-EMISSION-TOMOGRAPHY, NEUROENDOCRINE TUMORS, CHROMOGRANIN-A, CARBIDOPA PRETREATMENT, CONSENSUS GUIDELINES, SOLID TUMORS, SEGMENTATION, EXTRACTION, SURVIVAL, CRITERIA
journal title
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Eur. J. Nucl. Med. Mol. Imaging
volume
38
issue
10
pages
1854 - 1861
Web of Science type
Article
Web of Science id
000294684400009
JCR category
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
JCR impact factor
4.991 (2011)
JCR rank
8/116 (2011)
JCR quartile
1 (2011)
ISSN
1619-7070
DOI
10.1007/s00259-011-1862-5
language
English
UGent publication?
no
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1922962
handle
http://hdl.handle.net/1854/LU-1922962
date created
2011-10-07 15:54:14
date last changed
2016-12-19 15:46:25
@article{1922962,
  abstract     = {Positron emission tomography (PET) using 6-[(18)F]fluoro-L-dihydroxyphenylalanine ((18)F-dopa) has an excellent sensitivity to detect carcinoid tumour lesions. (18)F-dopa tumour uptake and the levels of biochemical tumour markers are mediated by tumour endocrine metabolic activity. We evaluated whether total (18)F-dopa tumour uptake on PET, defined as whole-body metabolic tumour burden (WBMTB), reflects tumour load per patient, as measured with tumour markers. 
Seventy-seven consecutive carcinoid patients who underwent an (18)F-dopa PET scan in two previously published studies were analysed. For all tumour lesions mean standardised uptake values (SUVs) at 40\% of the maximal SUV and tumour volume on (18)F-dopa PET were determined and multiplied to calculate a metabolic burden per lesion. WBMTB was the sum of the metabolic burden of all individual lesions per patient. The 24-h urinary serotonin, urine and plasma 5-hydroxindoleacetic acid (5-HIAA), catecholamines (nor)epinephrine, dopamine and their metabolites, measured in urine and plasma, and serum chromogranin A served as tumour markers. 
All but 1 were evaluable for WBMTB; 74 patients had metastatic disease. (18)F-dopa PET detected 979 lesions. SUV(max) on (18)F-dopa PET varied up to 29-fold between individual lesions within the same patients. WBMTB correlated with urinary serotonin (r = 0.51) and urinary and plasma 5-HIAA (r = 0.78 and 0.66). WBMTB also correlated with urinary norepinephrine, epinephrine, dopamine and plasma dopamine, but not with serum chromogranin A. 
Tumour load per patient measured with (18)F-dopa PET correlates with tumour markers of the serotonin and catecholamine pathway in urine and plasma in carcinoid patients, reflecting metabolic tumour activity.},
  author       = {Helle-Brit, Fiebrich and de Jong, Johan R and Kema, Ido P and Koopmans, Klaas Pieter and Sluiter, Wim and Dierckx, Rudi and Walenkamp, Annemiek M and Links, Thera P and Brouwers, Adrienne H and de Vries, Elisabeth GE},
  issn         = {1619-7070},
  journal      = {EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING},
  keyword      = {Carcinoid tumour,(18)F-dopa PET,Whole-body metabolic tumour burden,5-HIAA,POSITRON-EMISSION-TOMOGRAPHY,NEUROENDOCRINE TUMORS,CHROMOGRANIN-A,CARBIDOPA PRETREATMENT,CONSENSUS GUIDELINES,SOLID TUMORS,SEGMENTATION,EXTRACTION,SURVIVAL,CRITERIA},
  language     = {eng},
  number       = {10},
  pages        = {1854--1861},
  title        = {Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour},
  url          = {http://dx.doi.org/10.1007/s00259-011-1862-5},
  volume       = {38},
  year         = {2011},
}

Chicago
Helle-Brit, Fiebrich, Johan R de Jong, Ido P Kema, Klaas Pieter Koopmans, Wim Sluiter, Rudi Dierckx, Annemiek M Walenkamp, Thera P Links, Adrienne H Brouwers, and Elisabeth GE de Vries. 2011. “Total 18F-dopa PET Tumour Uptake Reflects Metabolic Endocrine Tumour Activity in Patients with a Carcinoid Tumour.” European Journal of Nuclear Medicine and Molecular Imaging 38 (10): 1854–1861.
APA
Helle-Brit, F., de Jong, J. R., Kema, I. P., Koopmans, K. P., Sluiter, W., Dierckx, R., Walenkamp, A. M., et al. (2011). Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 38(10), 1854–1861.
Vancouver
1.
Helle-Brit F, de Jong JR, Kema IP, Koopmans KP, Sluiter W, Dierckx R, et al. Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2011;38(10):1854–61.
MLA
Helle-Brit, Fiebrich, Johan R de Jong, Ido P Kema, et al. “Total 18F-dopa PET Tumour Uptake Reflects Metabolic Endocrine Tumour Activity in Patients with a Carcinoid Tumour.” EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 38.10 (2011): 1854–1861. Print.